SCHEMBL4965635

SCHEMBL4965635

O=C(O)N1CCN(c2ccc(C3(C(=O)NC4CCCCC4)CC3)c(F)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 6/20 0.43
HTT P42858 4/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GFER P55789 1/20 0.43
ALOX12 P18054 2/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.41
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
KCNH2 Q12809 1/20 0.37
GAA P10253 1/20 0.37
MMP13 P45452 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.36
RORA P35398 1/20 0.35
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6408605 0.90 TDP1 (0.44) SMN1; SMN2MAPTHTTMEN1KMT2A
SCHEMBL4962318 0.89 MAPT (0.47) SMN1; SMN2MAPTHTTMEN1KMT2A
SCHEMBL4964668 0.89 MAPT (0.47) SMN1; SMN2MAPTHTTMEN1KMT2A
SCHEMBL4965152 0.88 LMNA (0.43) SMN1; SMN2MAPTHTTMEN1KMT2A
SCHEMBL5950986 0.88 SMN1; SMN2 (0.43) SMN1; SMN2MAPTHTTMEN1KMT2A
Hydrochloric Acid SCHEMBL4966853 0.85 BMPR1B (0.42) SMN1; SMN2MAPTHTTMEN1KMT2A
SCHEMBL4964952 0.80 PDK2 (0.45) SMN1; SMN2MAPTMEN1KMT2AGFER
SCHEMBL4964877 0.80 PDK2 (0.45) SMN1; SMN2MAPTMEN1KMT2AGFER
SCHEMBL4011307 0.79 PDK2 (0.44) SMN1; SMN2MAPTMEN1KMT2AGFER
SCHEMBL5950347 0.79 PDK2 (0.44) SMN1; SMN2MAPTMEN1KMT2AGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP disclosed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 SMN1; SMN2 3497/4885MAPT 3691/4885HTT 3466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.